These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30401948)

  • 1. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.
    Tang G; Sydney Sir Philip JK; Weinberg O; Tam W; Sadigh S; Lake JI; Margolskee EM; Rogers HJ; Miranda RN; Bueso-Ramos C C; Hsi ED; Orazi A; Hasserjian RP; Arber DA; Bagg A; Wang SA
    Mod Pathol; 2019 Apr; 32(4):490-498. PubMed ID: 30401948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.
    Reiter A; Walz C; Watmore A; Schoch C; Blau I; Schlegelberger B; Berger U; Telford N; Aruliah S; Yin JA; Vanstraelen D; Barker HF; Taylor PC; O'Driscoll A; Benedetti F; Rudolph C; Kolb HJ; Hochhaus A; Hehlmann R; Chase A; Cross NC
    Cancer Res; 2005 Apr; 65(7):2662-7. PubMed ID: 15805263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?
    Bain BJ; Ahmad S
    Br J Haematol; 2014 Sep; 166(6):809-17. PubMed ID: 24913195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.
    Bousquet M; Quelen C; De Mas V; Duchayne E; Roquefeuil B; Delsol G; Laurent G; Dastugue N; Brousset P
    Oncogene; 2005 Nov; 24(48):7248-52. PubMed ID: 16091753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
    Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
    Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia.
    He R; Greipp PT; Rangan A; Mai M; Chen D; Reichard KK; Nelsen LL; Pardanani A; Hanson CA; Viswanatha DS
    Cancer Genet; 2016 May; 209(5):223-8. PubMed ID: 27134074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement-A 10-case study and literature review.
    Zhang L; Shah B; Zhang Y; Tashkandi H; Xiao W; Fernandez-Pol S; Vergara-Lluri M; Hussaini M; Song J; Lancet J; Moscinski L; Yun S; Lu CM; Medeiros LJ; Tang G
    Hum Pathol; 2023 Jun; 136():1-15. PubMed ID: 36958463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2.
    Pozdnyakova O; Orazi A; Kelemen K; King R; Reichard KK; Craig FE; Quintanilla-Martinez L; Rimsza L; George TI; Horny HP; Wang SA
    Am J Clin Pathol; 2021 Feb; 155(2):160-178. PubMed ID: 33367495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
    Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
    Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated genomic analysis using chromosomal microarray, fluorescence in situ hybridization and mate pair analyses: Characterization of a cryptic t(9;22)(p24.1;q11.2)/BCR-JAK2 in myeloid/lymphoid neoplasm with eosinophilia.
    Snider JS; Znoyko I; Lindsey KG; Morse J; Baughn LB; Hoppman NL; Pitel BA; Pearce KE; Schandl CA; Wolff DJ
    Cancer Genet; 2020 Aug; 246-247():44-47. PubMed ID: 32827877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature.
    Kantarcioglu B; Kaygusuz-Atagunduz I; Uzay A; Toptas T; Tuglular TF; Bayik M
    Int J Hematol; 2015 Sep; 102(3):383-7. PubMed ID: 25833723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and
    Lee WY; Pfau RB; Choi SM; Yang J; Xiao H; Putnam EM; Ryan RJ; Bixby DL; Shao L
    Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32238402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.
    Schwaab J; Knut M; Haferlach C; Metzgeroth G; Horny HP; Chase A; Tapper W; Score J; Waghorn K; Naumann N; Jawhar M; Fabarius A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2015 Feb; 94(2):233-8. PubMed ID: 25260694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5.
    Ehrentraut S; Nagel S; Scherr ME; Schneider B; Quentmeier H; Geffers R; Kaufmann M; Meyer C; Prochorec-Sobieszek M; Ketterling RP; Knudson RA; Feldman AL; Kadin ME; Drexler HG; MacLeod RA
    PLoS One; 2013; 8(1):e53767. PubMed ID: 23372669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid neoplasms with eosinophilia.
    Reiter A; Gotlib J
    Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained Response to Ruxolitinib of Eosinophilia-Associated Myeloproliferative Neoplasm with Translocation t(8;9)(p21;p24).
    Cai P; Liu S; Duan L; Huo L; Wu D; Chen S; Yang R; Yang X
    Acta Haematol; 2023; 146(5):397-400. PubMed ID: 37562364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.
    Shao H; Wang W; Song J; Tang G; Zhang X; Tang Z; Srivastava J; Shah B; Medeiros LJ; Zhang L
    Leuk Res; 2020 Dec; 99():106460. PubMed ID: 33166908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolutional change of karyotype with t(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia.
    Huang KP; Chase AJ; Cross NCP; Reiter A; Li TY; Wang TF; Chu SC; Lu XY; Li CC; Kao RH
    Int J Hematol; 2008 Sep; 88(2):197-201. PubMed ID: 18594780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies.
    Van Roosbroeck K; Ferreiro JF; Tousseyn T; van der Krogt JA; Michaux L; Pienkowska-Grela B; Theate I; De Paepe P; Dierickx D; Doyen C; Put N; Cools J; Vandenberghe P; Wlodarska I
    Genes Chromosomes Cancer; 2016 May; 55(5):428-41. PubMed ID: 26850007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathology of the bone marrow and spleen in a case of myelodysplastic/myeloproliferative neoplasm associated with t(8;9)(p22;p24) involving PCM1 and JAK2 genes.
    Dargent JL; Mathieux V; Vidrequin S; Deghorain X; Vannuffel P; Rack K
    Eur J Haematol; 2011 Jan; 86(1):87-90. PubMed ID: 21070368
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.